Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2271-2277

  Solomayer, E F ^a   Gebauer, G ^b   Hirnle, P ^c   Janni, W ^d   Luck H J ^e   Becker, S ^a   Huober, J ^f   Kramer B ^a   Wackwitz, B ^g   Wallwiener, D ^h   Fehm, T ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c OWL University   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f Department of Senologie   (Switzerland)

^g Department of Medical Affairs   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer; Disseminated tumor cells; Metastasis; Recurrence; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CELL COUNT; CIRCULATING TUMOR CELL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; DYSESTHESIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HOT FLUSH; HUMAN; LACRIMATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OSTEOMYELITIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT OUTCOME; VOMITING; WOUND INFECTION;

EID: 84864317505     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr612     Document Type: Article

References (27)

1. Garcia M, Jemal A, Ward EM et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society 2007.
2. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis 2006; 26: 65-74.
3. Solomayer EF, Diel IJ, Meyberg GC et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000; 59: 271-278.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-1594.
5. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009; 84: 533-545.
6. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22: 941-950.
7. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
8. Bidard FC, Vincent-Salomon A, Gomme S et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14: 3306-3311.
9. Bidard FC, Kirova YM, Vincent-Salomon A et al. Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol 2009; 20: 1836-1841.
10. Becker S, Solomayer E, Becker-Pergola G et al. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 2007; 106: 239-243.
11. Eidtmann H, Bundred N, De Boer R et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2009; 69 (Suppl): 74s-75s (Abstr 44).
12. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
13. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428.
14. Rack B, Juckstock J, Genss EM et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010; 30: 1807-1813.
15. Lin AY, Park JW, Scott J et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008; 26 (Suppl): 20s (Abstr 559).
16. Zometa® (zoledronic acid) Injection [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2011.
17. US Food and Drug Administration. CFR-Code of Federal Regulations Title 21: Title 21-Food and Drugs Chapter I-Food and Drug Administration Department of Health and Human Services Subchapter A-General Provisions: Part 50- Protection of Human Subjects. http://www.accessdata.fda.gov/SCRIPTs/cdrh/ cfdocs/cfcfr/CFRSearch.cfm. (22 December 2010, date last accessed).
18. Directive 2001/83/EC of The European Parliament and of The Council of 6 November 2001 on the Community Code relating to medicinal products for human use. Official Journal L-311, 28/11/2004, pp. 67-128. http://www. emea.europa.eu/pdfs/human/pmf/2001-83-EC.pdf. (22 December 2010, date last accessed).
19. Fehm T, Braun S, Muller V et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006; 107: 885-892.
20. Bauer KD, de la Torre-Bueno J, Diel IJ et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000; 6: 3552-3559.
21. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010; 37Suppl 1S53-S65.
22. Coleman RE, Winter MC, Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010; 102: 1099-1105.
23. Brufsky A, Bundred N, Coleman R et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008; 13: 503-514.
24. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
25. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009; 125: 1705-1709.
26. Borgen E, Pantel K, Schlimok G et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006; 70B: 400-409.
27. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34: 453-475.